Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008

    NANJING, China, July 15 /EMWNews-FirstCall/ -- Simcere

Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of

branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals

in the rapidly growing China market, announced today that it intends to

release its 2008 second quarter results on Tuesday, August 5, 2008, before

the market opens in the United States. Simcere's chief executive officer,

Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an

earnings conference call to discuss the company's 2008 second quarter

results on Tuesday, August 5, at 8 a.m. EDT (Tuesday, August 5, at 8 p.m.

Beijing/Hong Kong time).



    To access the conference call, please dial:



    United States toll-free dial-in number: +1.866.510.0704






    United States dial-in number:                +1.617.597.5362

    China toll-free dial-in number:              10.800.130.0399

    Hong Kong dial-in number:                    +852.3002.1672



    Please ask to be connected to Simcere's Q2 2008 Earnings Call and

provide the following passcode: 25912661. Simcere will also broadcast a

live audio webcast of the conference call. The broadcast will be available

by visiting the "Investor Relations" section of the company's Web site at

http://www.simcere.com.



    Following the earnings conference call, an archive of the call will be

available by dialing:



    United States toll-free dial-in number: +1.888.286.8010






    United States dial-in number:                +1.617.801.6888



    The passcode for replay participants is: 83949361. The telephone replay

also will be archived on the "Investor Relations" section of the company's

Web site at http://www.simcere.com for seven days following the earnings

announcement.

    About Simcere Pharmaceutical Group



    Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and

supplier of branded generic and innovative anti-cancer pharmaceuticals in

the rapidly growing China market. In recent years, Simcere Pharmaceutical

Group has focused its strategy on the development of first-to-market

generic and innovative pharmaceuticals, and has introduced a

first-to-market generic anti-stroke medication under the brand name Bicun

and an innovative anti-cancer medication under the brand name Endu. It

currently manufactures and sells 39 principal pharmaceutical products

including antibiotics, anti-cancer medication and anti-stroke medication

and is the exclusive distributor of three additional pharmaceuticals that

are marketed under its brand names. Simcere concentrates its research and

development efforts on the treatment of diseases with high incidence and/or

mortality rates and for which there is a clear demand for more effective

pharmacotherapy such as cancer, strokes, osteoporosis and infectious

diseases. For more information about Simcere Pharmaceutical Group, please

visit http://www.simcere.com.






    For investor and media inquiries, please contact:



    Email: [email protected]



    In Nanjing:



    Frank Zhigang Zhao

    Chief Financial Officer

    Simcere Pharmaceutical Group

    Tel: +86-25-8556 6666 ext. 8818



    In Beijing:



    Kejia Wu

    Brunswick Group

    Tel: +8610 6566 2256



    In Hong Kong:



    Joseph Lo Chi-Lun

    Brunswick Group

    Tel: +852 3512 5000



    In New York:



    Michael Guerin

    Brunswick Group LLC

    Tel: +1-212-333-3810